No Data
Asymchem Laboratories (06821.HK) received a Shareholding increase of 0.1623 million H shares, worth approximately 10.6678 million Hong Kong dollars.
On May 23, according to documents disclosed by the Hong Kong Stock Exchange on May 23, Schroders PLC increased its shareholding in Asymchem Laboratories (06821.HK) by 162,300 H-shares at an average price of HKD 65.7291 per share on May 22, valued at approximately HKD 10.6678 million. After the increase, Schroders' latest shareholding amounted to 5.2862 million shares, raising the shareholding ratio from 18.60% to 19.19%. Source of the image: Hong Kong Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (holding 5% or more)
Bullish raid! The Hong Kong stock market's pharmaceutical Sector has surged across the board. How will it develop in the future?
Super track explosion.
With continued decrease in volume and fluctuations, the market may face a choice of direction. Can innovative drugs and AI bear the banner of counterattack?
Track the entire lifecycle of the main Sector.
Asymchem Laboratories (06821.HK) received a shareholding increase of 738,900 H-shares from Schroders, valued at approximately 47.6734 million Hong Kong dollars.
On May 22, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on May 22, Schroders PLC increased its shareholding in $Asymchem Laboratories (06821.HK)$ by acquiring 738,900 H-shares at an average price of HKD 64.5194 per share on May 21, with a total value of approximately HKD 47.6734 million. After the increase, Schroders' latest shareholding amount is 5.1239 million shares, and the shareholding ratio rose from 15.91% to 18.60%. Image source: Stock disclosures from the Exchange. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more)
[Broker Focus] Zhongtai: The growth of the CDMO Sector excluding COVID-19 remains steady, and the demand for macromolecules and XDC CDMO is expected to increase.
Jinwu Financial News | Zhongtai has released a research report stating that the CRO and CDMO sectors, excluding COVID growth, continue to show stable performance in 2024, with significant recovery expected in Q1 2025, indicating a turning point has been reached. On the CDMO side, due to the rapid volume increase of downstream products, the production demand for chemical macromolecules and XDC CDMO such as peptides and oligonucleotides is expected to rise quickly, and investment opportunities in relevant industrial chains remain Bullish; as global investment and financing gradually recover and front-end projects continue to extend to the back-end, the small molecule CDMO sector is expected to gradually recover, suggesting to pay attention.
Highlights from the brokerage morning meeting: It is expected that this year's key vaccine varieties will likely resume sales growth trends under a low base.
In today's brokerage morning meeting, GUOTAI HAITONG SEC believes that the coal Industry has fully released risks, and an upward trend can be expected; Zhongtai stated that the Sector is expected to gradually recover, and continuous attention should be paid to clinical CRO investment opportunities; China Securities Co.,Ltd. pointed out that this year's major vaccine varieties are expected to restore the sales growth trend due to a low base.
